Altimmune (NASDAQ:ALT - Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.34) per share for the quarter. Parties that wish to register for the company's conference call can do so using this link.
Altimmune Stock Down 3.3 %
Shares of ALT traded down $0.20 during trading on Tuesday, reaching $5.91. The company's stock had a trading volume of 2,366,589 shares, compared to its average volume of 2,158,589. The company has a market cap of $420.32 million, a price-to-earnings ratio of -3.81 and a beta of 0.19. The company has a fifty day moving average of $6.95 and a two-hundred day moving average of $7.20. Altimmune has a twelve month low of $5.28 and a twelve month high of $14.84.
Analyst Upgrades and Downgrades
ALT has been the topic of several recent analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $12.00 price target on shares of Altimmune in a report on Wednesday, February 5th. UBS Group started coverage on shares of Altimmune in a research report on Tuesday, November 12th. They issued a "buy" rating and a $26.00 target price for the company. Finally, Stifel Nicolaus assumed coverage on shares of Altimmune in a research report on Wednesday, January 8th. They set a "buy" rating and a $18.00 price target on the stock. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Altimmune currently has a consensus rating of "Buy" and a consensus price target of $20.83.
Read Our Latest Report on ALT
Altimmune Company Profile
(
Get Free Report)
Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.
Read More
Before you consider Altimmune, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Altimmune wasn't on the list.
While Altimmune currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
